Cartesian Therapeutics (RNAC) - Stock & Dividends
Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US8162121045
Cartesian Therapeutics Inc., listed as RNA Corporation (NASDAQ: RNAC), is a biopharmaceutical company in the clinical-stage that focuses on developing cutting-edge nanoparticle immunomodulatory drugs to tackle various human diseases. The company's primary gene therapy project, SEL-302, is currently in Phase I clinical trials to boost the treatment for methylmalonic acidemia.
Furthermore, Cartesian Therapeutics is actively working on biologic therapies like SEL-212, currently in Phase III clinical trials for chronic refractory gout treatment. The company is also researching product candidates to address IgA-mediated disorders such as IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. Additionally, the company is exploring gene therapies aimed at tackling diseases like pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorders, and autoimmune diseases.
Moreover, Cartesian Therapeutics has inked license and collaboration agreements with various prominent entities including Ginkgo Bioworks Holdings, Genovis AB (publ.), Cyrus Biotechnology, and many more. Founded in 2007, Cartesian Therapeutics is headquartered in Watertown, Massachusetts.
To learn more about Cartesian Therapeutics Inc., visit their website at https://selectabio.com.
Drawdown (Underwater) Chart
RNAC Stock Overview
| Market Cap in USD | 102m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC SubIndustry | Biotechnology |
| TER | 0.00% |
| IPO / Inception | 2016-06-22 |
RNAC Stock Ratings
| Growth 5y | -4.83 |
| Fundamental | -72.1 |
| Dividend | - |
| Rel. Performance vs Sector | -3.71 |
| Analysts | 4.00/5 |
| Fair Price Momentum | 20.73 USD |
| Fair Price DCF | - |
RNAC Dividends
| Yield 12m | 0.00% |
| Yield on Cost 5y | 0.00% |
| Dividends CAGR 5y | 0.00% |
| Payout Consistency | 0.0% |
RNAC Growth Ratios
| Growth 12m | -20.99% |
| Growth Correlation 12m | -59% |
| Growth Correlation 3m | -15% |
| CAGR 5y | -17.94% |
| Sharpe Ratio 12m | -0.27 |
| Alpha vs SP500 12m | -58.89 |
| Beta vs SP500 5y weekly | 1.59 |
| ValueRay RSI | 98.67 |
| Volatility GJR Garch 1y | 78.01% |
| Price / SMA 50 | 32.16% |
| Price / SMA 200 | -4.23% |
| Current Volume | 137.4k |
| Average Volume 20d | 129.8k |
External Links for RNAC Stock
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X (Twitter) • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
As of May 05, 2024, the stock is trading at USD 25.60 with a total of 137,405 shares traded.
Over the past week, the price has changed by +21.73%, over one month by +74.11%, over three months by +20.56% and over the past year by -25.80%.
According to ValueRays Forecast Model, RNAC Cartesian Therapeutics will be worth about 23.3 in May 2025. The stock is currently trading at 25.60. This means that the stock has a potential downside of -9.1%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 55.5 | 117 |
| Analysts Target Price | 3.5 | -86.3 |
| ValueRay Target Price | 23.3 | -9.10 |